Muscle Spasticity
4
Pipeline Programs
4
Companies
6
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
PathMaker NeurosystemsMA - Boston
2 programsMyoRegulator®N/A1 trial
MyoRegulator® deviceN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IpsenBotulinum toxin type A
TevaTizanidine
Motric BioMTR-601
TevaTizanidine
PathMaker NeurosystemsMyoRegulator® device
PathMaker NeurosystemsMyoRegulator®
Clinical Trials (6)
Total enrollment: 187 patients across 6 trials
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
Start: Feb 2003Est. completion: Oct 2007162 patients
Phase 4Completed
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Start: Dec 2006Est. completion: Feb 200720 patients
Phase 1/2Completed
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
Start: Sep 2023Est. completion: Oct 2024
Phase 1Completed
Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)
Start: Dec 2006Est. completion: May 20075 patients
Phase 1Completed
Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity
Start: Mar 2022Est. completion: Jun 2024
N/ATerminated
Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke
Start: Jul 2018Est. completion: Jan 2021
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space